Table 2.
Insulin sensitivity
| Testosterone | Placebo | |||||
|---|---|---|---|---|---|---|
| Start | 3 months | 6 months | Start | 3 months | 6 months | |
| Basal Rd (mg/min/m2) |
78.5 (74.0–84.5) | 77.4 (72.7–82.3) | 77.0 (74.5–81.3) | 84.4 (77.4–92.7) | 83.2 (76.9–89.2) | 77.1 (71.6–82.5) |
| Insulin-stimulated Rd (mg/min/m2) |
207.0 (149.5–279.0) | 223.8 (140.1–279.7) | 238.65 (175.4–288.6) | 189.1 (148.0–350.1) | 244.8 (173.4–301.8) | 234.9 (174.2–284.6) |
| Basal HGP (mg/min/m2) | 80.1 ± 10.1 | 76.7 ± 9.0 | 76.0 ± 6.8 | 81.8 ± 13.0 | 79.9 ± 9.2 | 72.8 ± 18.7 |
| Insulin-suppressed HGP (mg/min/m2) |
32.2 (25.8–49.6) | 30.3 (20.8–41.3) | 27.4 (22.9–36.9) | 35.8 (27.9–45.6) | 33.5 (28.8–40.3) | 32.4 (26.3–39.7) |
| FFA fasting (mmol/l) | 0.49 ± 0.22 | 0.53 ± 0.17 | 0.49 ± 0.15 | 0.45 ± 0.14 | 0.45 ± 0.17 | 0.45 ± 0.16 |
| FFA insulin-stimulated (mmol/l) |
0.04 (0.03–0.07) | 0.06 (0.04–0.08)* | 0.04 (0.03–0.06) | 0.06 (0.05–0.08) | 0.04 (0.03–0.06) | 0.03 (0.03–0.04) |
| Insulin fasting (mIU/L) |
52 (36–96) | 56 (42–96) | 48 (39–109) | 56 (36–65) | 44 (37–83) | 49 (33–75) |
| Insulin clamp (mIU/L) |
427 (391–493) | 455 (419–514) | 441 (365–517) | 371 (332–467) | 410 (373–440) | 417 (380–440) |
Values are given as mean ± SD or median (interquartile range) as appropriate
*p < 0.05 compared to placebo; **p < 0.01 compared to placebo